Neurofix
Discovers and develops molecules for the treatment of pathologies of the central nervous system.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD5—7m (Dealroom.co estimates Feb 2023.)
Company register number A37542834
Villamayor Castile and León (HQ), Salamanca Castile and León (founding location)
Financials
Estimates*
EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | <1m | - | <1m | - | <1m | <1m | <1m |
% growth | 5579 % | - | - | - | - | - | 334 % |
EBITDA | (<1m) | (<1m) | <1m | (<1m) | (<1m) | (<1m) | - |
% EBITDA margin | (99 %) | - | 100 % | - | (4357 %) | (5208 %) | - |
Profit | (<1m) | (<1m) | <1m | (<1m) | (<1m) | (<1m) | - |
% profit margin | (75 %) | - | 66 % | - | (226 %) | (3148 %) | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
$250k | Debt | ||
€900k | Seed | ||
* | €750k | Seed | |
Total Funding | CAD2.5m |
Related Content
Recent News about Neurofix
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.